Drug Delivery System最新文献_第7页

Development of broadly reactive antibody therapeutics for SARS-CoV-2 针对严重急性呼吸系统综合征冠状病毒2型的广泛反应性抗体疗法的开发

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.388

Saya Moriyama

{"title":"Development of broadly reactive antibody therapeutics for SARS-CoV-2","authors":"Saya Moriyama","doi":"10.2745/dds.37.388","DOIUrl":"https://doi.org/10.2745/dds.37.388","url":null,"abstract":"Various antibody therapeutics has been developed for the treatment and suppression of the 2019 outbreak of novel coronavirus（SARS-CoV-2）infection. A major limitation in the development of SARS-CoV-2 neutralizing antibodies is the occurrence and spread of escape variants that have mutations in the spike glycoprotein. The coronaviruses are carried by various wild animals, domestic animals, and pets, and there have been cases of Severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus transmission from animals to people, resulting in a large spread of infection in people. There is also a possibility that cross-species transmission of SARS-CoV-2 may occur in the future. Considering these factors, the development of antibody therapeutics with broad cross-reactivity against SARS-CoV-2 variants and other coronaviruses is required.Alternate :抄録2019年に発生した新型コロナウイルス（SARS-CoV-2）感染症の治療や発症抑制のためにさまざまな抗体医薬の開発が進められている。SARS-CoV-2中和抗体の開発で大きな障壁となるのが、スパイク糖タンパク質に変異をもつ変異株の発生と感染拡大である。またコロナウイルスは多くの野生動物や家畜、愛玩動物が保有しており、これまでにも重篤呼吸器症候群コロナウイルスや中東呼吸器症候群コロナウイルスが動物からヒトへ伝播して大きく感染が広がったケースがある。SARS-CoV-2についても動物が起源であると考えられており、今後も種を越えた伝播が発生する可能性が考えられる。これらを踏まえて、SARS-CoV-2変異株や類縁コロナウイルスに対する交差反応性に優れた抗体医薬の開発が求められる。","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45625062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The 38th Annual Meeting of the Cyclodextrin Symposium, Japan 第38届环糊精年会，日本

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.452

T. Higashi

引用次数: 0

Current Status and Prospects of Vaccines based on DDS Technology 基于DDS技术的疫苗研究现状与展望

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.402

Atsushi Kawai, Toshiro Hirai, Yasushi Yoshioka

{"title":"Current Status and Prospects of Vaccines based on DDS Technology","authors":"Atsushi Kawai, Toshiro Hirai, Yasushi Yoshioka","doi":"10.2745/dds.37.402","DOIUrl":"https://doi.org/10.2745/dds.37.402","url":null,"abstract":"The development of DDS technology has contributed critically to the unprecedentedly rapid requirement for vaccines against COVID-19. LNP-based mRNA vaccines represent a subset of emerging DDS technology. Despite the groundbreaking nature of these vaccines, they are yet to be perfected and as such, new technologies are being developed to optimize these vaccines. This review will focus on exploring one of the modalities of recombinant protein vaccines and will introduce various findings on the enhancement of vaccine efficacy using antigen modification technologies, including VLPs and Fc-fusion proteins, and adjuvant improvements.Alternate :抄録COVID-19に対してかつてない速度でワクチンが普及した背景には、DDS技術の発展が必要不可欠であった。特に、mRNAワクチンにおける脂質ナノ粒子（LNP）の開発は、まさにDDS技術の結集といえよう。一方で、mRNAワクチンを含め、現状のさまざまなワクチンは多くの課題を有しており、より効果的かつ安全なワクチン開発に資する基盤技術の確立が世界的に待望されている。本稿では、ワクチンモダリティの1つである組換えタンパク質ワクチンに焦点を絞り、抗原改変技術からアジュバントの改良に至るまで、ワクチン開発基盤技術の最新知見について紹介する。","PeriodicalId":11331,"journal":{"name":"Drug Delivery System","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47316177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3D imaging techniques 三维成像技术

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.444

S. Fumoto, Taiga Takahashi

引用次数: 0

Development of mucosal vaccine based on DDS 基于DDS的黏膜疫苗的研制

Drug Delivery System Pub Date : 2022-11-25 DOI: 10.2745/dds.37.412

Koji Hosomi, J. Kunisawa

引用次数: 0

Oral drug delivery for personalized medicine 个性化药物的口服给药

Drug Delivery System Pub Date : 2022-09-25 DOI: 10.2745/dds.37.281

T. Takagi